Status:
UNKNOWN
Vaginal Dinoprostone Versus Isonicotinic Acid Hydrazide Prior to Diagnostic Office Hysteroscopy
Lead Sponsor:
Aswan University Hospital
Conditions:
Postmenopausal Bleeding
Eligibility:
FEMALE
45-60 years
Phase:
NA
Brief Summary
To compare the effectiveness of vaginal dinoprostone and vaginal Isonicotinic acid hydrazide in minimizing the pain experienced by postmenopausal patients during diagnostic office hysteroscopy and to a...
Detailed Description
hysteroscopy is commonly used in the diagnosis and treatment of intrauterine lesions such as polyps, fibroids, septa, and adhesions, and in the presence of abnormal bleeding and during the removal of a...
Eligibility Criteria
Inclusion
- Menopausal patients with an indication for office hysteroscopy (postmenopausal bleeding or abnormal ultrasound findings)
Exclusion
- Nulliparous patients
- patients with cervical pathology
- retroverted uterus (detected by transvaginal ultrasound)
- previous cervical surgery
- patients with severe vaginal bleeding
- allergy or contraindications to dinoprostone or INH therapy
Key Trial Info
Start Date :
September 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 30 2022
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04500496
Start Date
September 1 2020
End Date
January 30 2022
Last Update
September 29 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aswan University Hospital
Aswān, Egypt, 81528